Research Only Cognitive & Nootropic

Dynorphin

also known as: Dynorphin A, Dynorphin B, Big Dynorphin, Dyn A

The brain's 'anti-reward' opioid — a kappa-receptor agonist that produces dysphoria rather than euphoria, critical to understanding addiction, stress, and depression.

A family of opioid peptides derived from prodynorphin that selectively activate kappa-opioid receptors (KOR), producing dysphoria, stress responses, and anti-reward signaling — the pharmacological opposite of beta-endorphin's euphoric effects.

Mechanism of action

Selectively binds kappa-opioid receptors (KOR), activating Gi/o signaling. KOR activation in the nucleus accumbens reduces dopamine release (anti-reward), in the dorsal raphe reduces serotonin release (prodepressant), and in the locus coeruleus enhances norepinephrine-mediated stress responses. Upregulated by chronic stress and drug withdrawal, dynorphin/KOR signaling drives the negative affective states that perpetuate addiction cycles.

Primary uses

Endogenous stress and anti-reward signaling
Research target for addiction neuroscience (KOR antagonists for relapse prevention)
Depression research (KOR antagonists as novel antidepressants)
Pain modulation (spinal dynorphin contributes to chronic pain chronification)

Typical dosing

N/A N/A N/A (endogenous)

Not used therapeutically. Research focuses on KOR antagonists to block dynorphin's effects. Elevated CSF dynorphin levels are associated with chronic pain states and major depression.

Regulatory status

Not approved as a drug. KOR antagonists (e.g., aticaprant in clinical trials for depression) aim to block dynorphin's dysphoric effects for treating depression and addiction.

References

[review] Bruchas MR, Land BB, Chavkin C. "The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors." Brain Res. 2010;1314:44-55.
[pubmed] Goldstein A, et al. "Dynorphin-(1-13), an extraordinarily potent opioid peptide." Proc Natl Acad Sci USA. 1979;76(12):6666-6670.

Related peptides

Beta-Endorphin

The body's most potent endogenous painkiller — the 31-amino-acid opioid peptide behind the 'runner's high' and natural pain modulation.

Enkephalin

The body's short-acting local painkillers — five-amino-acid opioid peptides that modulate pain, mood, and gut motility at the synaptic level.

Dermorphin

⚠ Potent mu-opioid agonist — ~30–40× more potent than morphine; has been misused as a horse-racing doping agent and carries serious overdose/dependence risk. Included for reference and harm-reduction only. Not a therapeutic or "longevity" peptide.

Substance P

The pain and nausea neuropeptide — an 11-amino-acid tachykinin that transmits pain signals and triggers vomiting, targeted by aprepitant (Emend) and the entire NK1 antagonist drug class.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.